Michael S. Wyzga's Insider Trades & SAST Disclosures
Michael S. Wyzga's most recent trade in Mereo Biopharma Group Plc - ADR was a trade of 55,000 Share Options (Right to buy) done . Disclosure was reported to the exchange on Feb. 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael S. Wyzga.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mereo Biopharma Group Plc ... | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 55,000 | 55,000 | - | - | Share Options (Right to buy) | |
| Mereo Biopharma Group Plc ... | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 30,487 | 30,487 | - | - | Deferred Restricted Stock Units | |
| Mereo Biopharma Group Plc ... | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 3.99 per share. | 17 Jun 2024 | 25,050 | 25,050 | - | 4.0 | 99,950 | American Depositary Shares representing Ordinary Shares |
| X4 Pharmaceuticals Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 121,667 (0%) | 0% | 0 | Common Stock | |
| Mereo Biopharma Group Plc ... | Stephen Michael Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 45,000 | 45,000 | - | - | Share Options (Right to buy) | |
| Mereo Biopharma Group Plc ... | Stephen Michael Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 30,783 | 30,783 | - | - | Deferred Restricted Stock Units | |
| X4 Pharmaceuticals Inc | Michael Stephen Wyzga | Director | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 18 Aug 2023 | 25,000 | 76,667 (0%) | 0% | 1.2 | 29,875 | Common Stock |
| Invivyd Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Invivyd Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| X4 Pharmaceuticals Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Invivyd Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2021 | 71,186 | 71,186 | - | - | Stock Option (Right to Buy) | |
| X4 Pharmaceuticals Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Exact Sciences Corp. | Michael Stephen Wyzga | Director | Sale of securities on an exchange or to another person at price $ 130.11 per share. | 26 Feb 2021 | 19,021 | 2,558 (0%) | 0% | 130.1 | 2,474,822 | Common Stock |
| Exact Sciences Corp. | Michael Stephen Wyzga | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2021 | 10,108 | 0 | - | - | Stock Option (right to buy) | |
| Exact Sciences Corp. | Michael Stephen Wyzga | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.98 per share. | 26 Feb 2021 | 10,108 | 21,579 (0%) | 0% | 27.0 | 272,714 | Common Stock |
| Exact Sciences Corp. | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 2,558 | 11,471 (0%) | 0% | 0 | Common Stock | |
| X4 Pharmaceuticals Inc | Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges